Cytosorbents (CTSO) Accounts Payables (2010 - 2026)

Cytosorbents has reported Accounts Payables for 17 years, with the latest figure at $3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 5.82% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $3.1 million (down 5.82% YoY), and the FY2025 full-year result was $2.9 million, down 14.1% from the prior year.
• Accounts Payables for Q1 2026 stood at $3.1 million, up from $2.9 million in the prior quarter.
• The five-year high for Accounts Payables was $4.8 million in Q1 2022, with the low at $1.7 million in Q4 2022.
• Historically, Accounts Payables has averaged $3.0 million across 5 years, with a median of $3.0 million in 2025.
• The largest YoY upside for Accounts Payables was 187.66% in 2022 against a maximum downside of 41.0% in 2022.
• Cytosorbents' Accounts Payables stood at $1.7 million in 2022, then surged by 129.71% to $3.8 million in 2023, then dropped by 12.16% to $3.3 million in 2024, then decreased by 14.1% to $2.9 million in 2025, then rose by 9.17% to $3.1 million in 2026.
• The last three Accounts Payables figures came in at $3.1 million (Q1 2026), $2.9 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.